
INDEPENDENT RESEARCH MEDIA HOUSE FOR THE ASX. DEPTH OVER HYPE.
Mesoblast (ASX MSB), Research and Coverage
Mesoblast Limited (ASX: MSB, Nasdaq: MESO) is a biotechnology company with its registered office in Melbourne. It listed on the ASX on 16 December 2004 (ASX company data). It makes cell therapies from the bone marrow cells of healthy adult donors. Its first product, Ryoncil, was approved by the US Food and Drug Administration on 18 December 2024 for children with a transplant complication called steroid-refractory acute graft versus host disease. Ryoncil net sales were US$115.2 million in the year to 30 June 2026, and the net loss was US$57.5 million (annual report, lodged 12 October 2026). Cash was US$98.5 million at 30 September 2026, with a US$125 million loan fully drawn (Appendix 4C quarterly cash flow report, lodged 29 October 2026). Samso had published 5 pieces on the company at 17 November 2026.
ASX code: MSB. Full legal name: Mesoblast Limited. Chief Executive Officer and Managing Director: Dr Silviu Itescu. Philip Facchina is the non-executive chair. The other directors are Jane Bell, Lyn Cobley, Jon Voigtman and Dr Gregory George, who is also interim Chief Operating Officer (ASX company data, read 17 November 2026, and ASX announcement, 10 November 2026). The shares also trade on Nasdaq as MESO.
Mesoblast products and their regulatory status
Mesoblast develops cell therapies for severe inflammatory diseases. Its products are allogeneic, which means they are made in advance from donor cells and not from each patient's cells. The cells are mesenchymal stromal cells and their precursors. They are taken from the bone marrow of healthy adult donors and grown. Mesoblast says the cells release factors that reduce inflammation (annual report, lodged 12 October 2026).
The FDA is the US Food and Drug Administration. A Biologics License Application, or BLA, is the filing that asks the FDA to approve a medicine made from living cells. A Phase 3 trial is the large trial an approval usually rests on. Its primary endpoint is the main result the trial is designed to measure.
- Ryoncil (remestemcel-L-rknd), United States. Approved by the FDA on 18 December 2024 for steroid-refractory acute graft versus host disease in children aged 2 months and older. In this complication of a bone marrow transplant, the donor's immune cells attack the patient. Steroid-refractory means steroids, the first treatment, have not worked. Ryoncil went on sale in the US on 27 March 2025. It is not approved for adults (annual report, lodged 12 October 2026).
- Ryoncil for Duchenne muscular dystrophy, United States. Not approved. This is an inherited disease of progressive muscle loss. In April 2026 the FDA cleared an Investigational New Drug application, the filing that allows a trial in people to start. Mesoblast plans a trial in 76 children aged 5 to 9 (ASX announcement, 8 April 2026).
- Rexlemestrocel-L for chronic low back pain, United States. Not approved. A Phase 3 trial finished treating its 350 patients in August 2026 (ASX announcement, 17 August 2026).
- Rexlemestrocel-L for heart failure, United States. Not approved. Mesoblast calls it Revascor for this use. It received a BLA filing number from the FDA in June 2026 and asked for the application to be reviewed in stages. The use sought is preventing life-threatening gastrointestinal bleeding in end-stage heart failure patients with an implanted heart pump. The company's presentation of 16 November 2026 lists completing the BLA filing as work still ahead (annual report, lodged 12 October 2026, ASX announcement, 1 July 2026, and investor presentation, 16 November 2026).
- Japan. JCR Pharmaceuticals, a licensee, sells a product called TEMCELL for acute graft versus host disease in children and adults. It received full approval in Japan in September 2015. Mesoblast receives a royalty on its sales (annual report, lodged 12 October 2026).
Ryoncil sales in the United States
Mesoblast sells Ryoncil to US hospitals that perform bone marrow transplants in children. More than 50 transplant centres had been signed up since launch (annual report, lodged 12 October 2026).
Ryoncil net sales were US$115.2 million in the year to 30 June 2026, its first full year on sale. Royalties added US$5.1 million, for total revenue of US$120.3 million. Revenue was US$17.2 million the year before (annual report, note 3, lodged 12 October 2026). For the September 2026 quarter the company reported Ryoncil net revenue of US$28 million. The figure was US$19 million a year earlier and US$36 million in the June 2026 quarter. The company says there is a seasonal pattern from summer treatment scheduling each July and August. It describes the September figure as a preliminary estimate, subject to closing and audit procedures (ASX announcements, 10 July and 16 October 2026).
The annual report describes the evidence as a single-arm Phase 3 trial in children, meaning a trial with no comparison group. In it, 70 per cent of patients had an overall response, meaning their disease had improved, by Day 28. The FDA granted Ryoncil seven years of orphan drug exclusivity. An orphan drug is one for a rare disease. Mesoblast says the FDA will not approve another mesenchymal stromal cell product for the same use in those seven years. The annual report also says the FDA can approve a later product it finds clinically superior, and that the exclusivity does not stop other types of drug (annual report, lodged 12 October 2026).
Mesoblast is running a trial to extend the approval to adults. It plans to enrol 180 adults with severe disease, half given the existing drug ruxolitinib and half given ruxolitinib with Ryoncil. The primary endpoint is overall response at Day 28. The trial is enrolling patients, and the company expects an interim analysis, an early look at the results, in the last quarter of calendar 2027 (quarterly report, lodged 29 October 2026, and investor presentation, 16 November 2026).
Rexlemestrocel-L trials in back pain and heart failure
Rexlemestrocel-L is Mesoblast's second product. For chronic low back pain caused by degenerative disc disease, one dose is injected into the damaged disc. The Phase 3 trial treated 350 patients with either the cells or a sham injection, a dummy procedure used for comparison. Its primary endpoint is pain reduction at 12 months (ASX announcement, 17 August 2026). An earlier Phase 3 trial of 404 patients did not meet its combined measures of pain and function. Mesoblast reports that the group given the cells with hyaluronic acid, the carrier used for the injection, had lasting reductions in pain against the saline group (annual report, lodged 12 October 2026).
Mesoblast reported in January 2026 that the FDA had confirmed a clinically meaningful reduction in pain at 12 months could support the product's efficacy (ASX announcement, 19 January 2026). The announcement of 17 August 2026 and the annual report expect results in mid-calendar 2027. The announcement of 10 November 2026 gives the second half of calendar 2027.
For heart failure, the cells are injected into the heart muscle. Two trials have been completed. A 159-patient Phase 2 trial, a smaller and earlier stage than Phase 3, tested the cells in end-stage patients with an implanted heart pump, called a left ventricular assist device. It did not show a significant difference in patients' ability to tolerate a 60-minute wean from the pump. A 565-patient Phase 3 trial did not reduce repeat heart failure events, its primary endpoint.
Mesoblast reports a lower rate of major bleeding events in the first trial and fewer heart attacks, strokes and cardiac deaths in the second. Neither was the primary endpoint of its trial. Its presentation labels the statistical result for bleeding as nominal, which usually means a figure not adjusted for the number of tests run (annual report, lodged 12 October 2026, and investor presentation, 16 November 2026).
Mesoblast first planned to seek accelerated approval, an FDA route that allows approval on earlier evidence with a confirming trial to follow. It now says it is filing for full approval (annual report, lodged 12 October 2026). It reports that the FDA confirmed the BLA filing may proceed for pump patients with life-threatening major gastrointestinal bleeding. Formal minutes of that meeting were still to come (quarterly report, lodged 29 October 2026).
Mesoblast revenue, cash and debt
Mesoblast made a net loss of US$57.5 million in the year to 30 June 2026, down from US$102.1 million. Operations used US$43.8 million of cash. Accumulated losses were US$1,068.4 million (annual report, lodged 12 October 2026).
In the September 2026 quarter Mesoblast received US$35.4 million from customers and used US$2.1 million in operations. The Appendix 4C, the quarterly cash flow form, divides the cash by that outflow and gives 46.3 quarters of funding. The sum uses operating cash only. Interest of US$2.7 million was paid in the quarter and is recorded under financing (Appendix 4C, lodged 29 October 2026).
The debt is a US$125 million five-year facility at a fixed 8 per cent a year, with interest only until December 2030. It is secured solely on the TEMCELL royalty. The lender is Dr Gregory George, a director and the largest shareholder. Mesoblast drew US$75 million in December 2025 and US$50 million in June 2026 and repaid two earlier lenders. The lender also receives warrants as a commitment fee. On 10 November 2026 shareholders approved the issue to Dr George of warrants over 3,225,756 shares at an exercise price of A$3.20 a share. The loan agreement has covenants, including a minimum unrestricted cash balance of US$25.0 million (annual report, note 5(e), notice of meeting, lodged 12 October 2026, and results of meeting, lodged 10 November 2026).
The accounts were prepared on a going concern basis. The directors expect cash and Ryoncil receipts to cover the next twelve months. They say more capital will be needed beyond that (annual report, lodged 12 October 2026).
At the annual general meeting on 10 November 2026 the remuneration report was carried with 27.94 per cent of votes against, and the results of meeting record a strike. A strike is a vote of 25 per cent or more against the report. Every other resolution was carried (results of meeting, lodged 10 November 2026).
Every Samso piece on Mesoblast
5 published pieces as at 17 November 2026, grouped by Samso product. Newest first in each group. Dates are Perth dates.
Samso News
- 12 Nov 2026, Gene Editing in 2026 and the ASX Cell and Gene Therapy Companies (four ASX companies, with a section on Mesoblast)
- 1 Oct 2025, Successful Commercial Launch of Ryoncil® Showcased at Global Healthcare Conferences - A Story About Allogeneic Cellular Medicines for Inflammatory Diseases.
- 24 Jul 2025, Mesoblast and FDA Align on Key Steps Toward Revascor® BLA Filing - A Solution for Chronic Heart Failure.
- 11 Jul 2025, Mesoblast Limited (ASX: MSB) – A Two-Pronged Regulatory Advance in Cellular Therapies.
- 4 Jun 2025, Mesoblast Ltd (ASX: MSB) - Pioneering Allogeneic Cellular Therapies. (the first Samso piece on the company)
Questions people ask about Mesoblast (ASX MSB)
What does Mesoblast do? It makes cell therapies from donor bone marrow cells. It sells one product, Ryoncil, in the United States. A second product, rexlemestrocel-L, has a Phase 3 trial in back pain awaiting results.
What is the Mesoblast share price? The ASX website shows the MSB share price. This page lists Samso's coverage and has no live price.
What is the latest announcement from Mesoblast? As at 17 November 2026 the newest items on the ASX list were a release and a presentation for the ASX Investor Day, both lodged on 16 November 2026.
Is Ryoncil approved? In the United States, yes, for children aged 2 months and older with steroid-refractory acute graft versus host disease. The FDA approved it on 18 December 2024. It is not approved for adults, and a trial in adults is enrolling.
Is Mesoblast worth looking at? This page gives no buy, sell or hold call, price target or valuation. Ryoncil net sales were US$115.2 million in the year to 30 June 2026, and the company made a net loss of US$57.5 million. The September 2026 quarter used US$2.1 million of cash in operations, before US$2.7 million of interest. The directors say more capital will be needed beyond the next twelve months. Rexlemestrocel-L is not approved in the United States, and its back pain trial has not reported results. Cash was US$98.5 million at 30 September 2026 against a US$125 million loan from a director. Samso has no research workup on Mesoblast. The Samso News piece of 12 November 2026 is the most recent.
Disclosure
Samso holds no shares in Mesoblast at 17 November 2026.
This page is general information only.
Depth over hype.
Samso company research pages are independent research commentary for general information only. Nothing on this page is financial product advice, and it does not take into account any reader's objectives, financial situation or needs. Figures are drawn from public sources believed reliable at the stated dates but are not guaranteed, and market-sensitive numbers change daily. Samso or associated parties may hold positions in, or have commercial arrangements with, companies mentioned. Seek professional advice before making investment decisions. © Samso 2026, samso.com.au
Page last reviewed 17 November 2026.